HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia

Background Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding. Methods Subjects in this retros...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer (Tokyo, Japan) Japan), 2023-09, Vol.30 (5), p.796-801
Main Authors: Rainone, Michael, Behrendt, Carolyn E., Kasparian, Saro, Nguyen, Tina, Sedrak, Mina S., Lavasani, Sayeh, Stewart, Daphne B., Yuan, Yuan, Mortimer, Joanne E., Waisman, James R., Patel, Niki, Pullarkat, Vinod
Format: Article
Language:English
Subjects:
Ado-Trastuzumab Emtansine - adverse effects
Analysis
Antibodies
Biopharmaceutics
Breast cancer
Breast Neoplasms - pathology
Cancer Research
Cycling
Drug therapy
Female
Health aspects
Humans
Immunoconjugates - therapeutic use
Maytansine
Medicine
Medicine & Public Health
Metastasis
Oncology
Original
Original Article
Receptor, ErbB-2 - genetics
Retrospective Studies
Surgery
Surgical Oncology
Thrombocytopenia
Thrombocytopenia - chemically induced
Thrombocytopenia - drug therapy
Trastuzumab - therapeutic use
Viral antibodies
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding. Methods Subjects in this retrospective cohort were female patients with HER2 positive breast cancer, of Asian or non-Hispanic White ancestry, who initiated T-DM1 or T-DXd from January 2017 through October 2021. Follow-up closed in January 2022. Primary endpoint was dose adjustment for thrombocytopenia. Competing endpoints were discontinuation of drug for other toxicity, disease progression, or for completion of prescribed cycles. The association between Asian ancestry and thrombocytopenia-related dose adjustment was tested at p  
ISSN:1340-6868
1880-4233
1880-4233
DOI:10.1007/s12282-023-01473-2